Report Overview
Report Summary
The global Meningococcal Group B Vaccine market is valued at million US$ in 2020 and will reach million US$ by the end of 2027, growing at a CAGR of during 2021-2027. The objectives of this study are to define, segment, and project the size of the Meningococcal Group B Vaccine market based on company, product type, end user and key regions.
This report studies the global market size of Meningococcal Group B Vaccine in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Meningococcal Group B Vaccine in these regions.
This research report categorizes the global Meningococcal Group B Vaccine market by top players/brands, region, type and end user. This report also studies the global Meningococcal Group B Vaccine market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.
The following manufacturers are covered in this report, with sales, revenue, market share for each company:
GSK
Pfizer
Market size by Product
Type 1
Type 2
Market size by End User
Public
Private
Market size by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
India
Japan
South Korea
Australia
Indonesia
Singapore
Malaysia
Philippines
Thailand
Vietnam
Europe
Germany
France
UK
Italy
Spain
Russia
Central & South America
Brazil
Rest of Central & South America
Middle East & Africa
GCC Countries
Turkey
Egypt
South Africa
The study objectives of this report are:
To study and analyze the global Meningococcal Group B Vaccine market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2020, and forecast to 2027.
To understand the structure of Meningococcal Group B Vaccine market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
Focuses on the key global Meningococcal Group B Vaccine companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
To project the value and sales volume of Meningococcal Group B Vaccine submarkets, with respect to key regions.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
In this study, the years considered to estimate the market size of Meningococcal Group B Vaccine are as follows:
History Year: 2017-2020
Base Year: 2020
Estimated Year: 2020
Forecast Year 2021 to 2027
This report includes the estimation of market size for value (million US$) and volume (K Units). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Meningococcal Group B Vaccine market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.
For the data information by region, company, type and application, 2020 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.
Table Of Contents
Table Of Contents
Table of Contents
1 Study Coverage
1.1 Meningococcal Group B Vaccine Product
1.2 Market Segments
1.3 Key Manufacturers Covered
1.4 Market by Type
1.4.1 Global Meningococcal Group B Vaccine Market Size Growth Rate by Product
1.4.2 Type 1
1.4.3 Type 2
1.5 Market by End User
1.5.1 Global Meningococcal Group B Vaccine Market Size Growth Rate by End User
1.5.2 Public
1.5.3 Private
1.6 Study Objectives
1.7 Years Considered
2 Executive Summary
2.1 Global Meningococcal Group B Vaccine Market Size
2.1.1 Global Meningococcal Group B Vaccine Revenue 2017-2027
2.1.2 Global Meningococcal Group B Vaccine Sales 2017-2027
2.2 Meningococcal Group B Vaccine Growth Rate by Regions
2.2.1 Global Meningococcal Group B Vaccine Sales by Regions
2.2.2 Global Meningococcal Group B Vaccine Revenue by Regions
3 Breakdown Data by Manufacturers
3.1 Meningococcal Group B Vaccine Sales by Manufacturers
3.1.1 Meningococcal Group B Vaccine Sales by Manufacturers
3.1.2 Meningococcal Group B Vaccine Sales Market Share by Manufacturers
3.1.3 Global Meningococcal Group B Vaccine Market Concentration Ratio (CR5 and HHI)
3.2 Meningococcal Group B Vaccine Revenue by Manufacturers
3.2.1 Meningococcal Group B Vaccine Revenue by Manufacturers (2017-2020)
3.2.2 Meningococcal Group B Vaccine Revenue Share by Manufacturers (2017-2020)
3.3 Meningococcal Group B Vaccine Price by Manufacturers
3.4 Meningococcal Group B Vaccine Manufacturing Base Distribution, Product Types
3.4.1 Meningococcal Group B Vaccine Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers Meningococcal Group B Vaccine Product Type
3.4.3 Date of International Manufacturers Enter into Meningococcal Group B Vaccine Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Breakdown Data by Product
4.1 Global Meningococcal Group B Vaccine Sales by Product
4.2 Global Meningococcal Group B Vaccine Revenue by Product
4.3 Meningococcal Group B Vaccine Price by Product
5 Breakdown Data by End User
5.1 Overview
5.2 Global Meningococcal Group B Vaccine Breakdown Data by End User
6 North America
6.1 North America Meningococcal Group B Vaccine by Countries
6.1.1 North America Meningococcal Group B Vaccine Sales by Countries
6.1.2 North America Meningococcal Group B Vaccine Revenue by Countries
6.1.3 United States
6.1.4 Canada
6.1.5 Mexico
6.2 North America Meningococcal Group B Vaccine by Product
6.3 North America Meningococcal Group B Vaccine by End User
7 Europe
7.1 Europe Meningococcal Group B Vaccine by Countries
7.1.1 Europe Meningococcal Group B Vaccine Sales by Countries
7.1.2 Europe Meningococcal Group B Vaccine Revenue by Countries
7.1.3 Germany
7.1.4 France
7.1.5 UK
7.1.6 Italy
7.1.7 Russia
7.2 Europe Meningococcal Group B Vaccine by Product
7.3 Europe Meningococcal Group B Vaccine by End User
8 Asia Pacific
8.1 Asia Pacific Meningococcal Group B Vaccine by Countries
8.1.1 Asia Pacific Meningococcal Group B Vaccine Sales by Countries
8.1.2 Asia Pacific Meningococcal Group B Vaccine Revenue by Countries
8.1.3 China
8.1.4 Japan
8.1.5 Korea
8.1.6 India
8.1.7 Australia
8.1.8 Indonesia
8.1.9 Malaysia
8.1.10 Philippines
8.1.11 Thailand
8.1.12 Vietnam
8.1.13 Singapore
8.2 Asia Pacific Meningococcal Group B Vaccine by Product
8.3 Asia Pacific Meningococcal Group B Vaccine by End User
9 Central & South America
9.1 Central & South America Meningococcal Group B Vaccine by Countries
9.1.1 Central & South America Meningococcal Group B Vaccine Sales by Countries
9.1.2 Central & South America Meningococcal Group B Vaccine Revenue by Countries
9.1.3 Brazil
9.2 Central & South America Meningococcal Group B Vaccine by Product
9.3 Central & South America Meningococcal Group B Vaccine by End User
10 Middle East and Africa
10.1 Middle East and Africa Meningococcal Group B Vaccine by Countries
10.1.1 Middle East and Africa Meningococcal Group B Vaccine Sales by Countries
10.1.2 Middle East and Africa Meningococcal Group B Vaccine Revenue by Countries
10.1.3 GCC Countries
10.1.4 Turkey
10.1.5 Egypt
10.1.6 South Africa
10.2 Middle East and Africa Meningococcal Group B Vaccine by Product
10.3 Middle East and Africa Meningococcal Group B Vaccine by End User
11 Company Profiles
11.1 GSK
11.1.1 GSK Company Details
11.1.2 Company Business Overview
11.1.3 GSK Meningococcal Group B Vaccine Sales, Revenue and Gross Margin (2017-2020)
11.1.4 GSK Meningococcal Group B Vaccine Products Offered
11.1.5 GSK Recent Development
11.2 Pfizer
11.2.1 Pfizer Company Details
11.2.2 Company Business Overview
11.2.3 Pfizer Meningococcal Group B Vaccine Sales, Revenue and Gross Margin (2017-2020)
11.2.4 Pfizer Meningococcal Group B Vaccine Products Offered
11.2.5 Pfizer Recent Development
12 Future Forecast
12.1 Meningococcal Group B Vaccine Market Forecast by Regions
12.1.1 Global Meningococcal Group B Vaccine Sales Forecast by Regions 2021-2027
12.1.2 Global Meningococcal Group B Vaccine Revenue Forecast by Regions 2021-2027
12.2 Meningococcal Group B Vaccine Market Forecast by Product
12.2.1 Global Meningococcal Group B Vaccine Sales Forecast by Product 2021-2027
12.2.2 Global Meningococcal Group B Vaccine Revenue Forecast by Product 2021-2027
12.3 Meningococcal Group B Vaccine Market Forecast by End User
12.4 North America Meningococcal Group B Vaccine Forecast
12.5 Europe Meningococcal Group B Vaccine Forecast
12.6 Asia Pacific Meningococcal Group B Vaccine Forecast
12.7 Central & South America Meningococcal Group B Vaccine Forecast
12.8 Middle East and Africa Meningococcal Group B Vaccine Forecast
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
13.1 Market Opportunities and Drivers
13.2 Market Challenges
13.3 Market Risks/Restraints
13.4 Macroscopic Indicators
14 Value Chain and Sales Channels Analysis
14.1 Value Chain Analysis
14.2 Meningococcal Group B Vaccine Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
16.3 Disclaimer